Objective:

To evaluate the concentration of circulating cardiotonic steroids (CTS) and their relationship with specific clinical outcomes, such as quality of life and hospitalization rates, in patients with atrial fibrillation (AF) and heart failure (HF) undergoing treatment with digoxin or beta-blockers.

Key Findings:

• Low-dose digoxin was equivalent to beta-blockers for quality of life and superior for other clinical outcomes, indicating its potential as a preferred treatment option.
• Elevated levels of endogenous CTS correlated with clinical outcomes in patients with AF and HF, suggesting a role in disease management.
• The study provided insights into the potential interaction between digoxin and circulating CTS, which may inform future therapeutic strategies.

Interpretation:

The findings suggest that circulating CTS may influence the efficacy of digoxin in managing AF and HF, highlighting the need for further research on their clinical implications and potential for personalized treatment approaches.

Limitations:

• The study was limited to a specific cohort, which may not be generalizable to all AF and HF patients, potentially affecting the applicability of the results.
• Potential confounding factors related to comorbidities and concurrent medications were not fully addressed, which may influence the observed relationships.

Conclusion:

This study represents the first systematic evaluation of CTS levels in relation to clinical outcomes in AF and HF patients, suggesting a complex interplay between digoxin and endogenous CTS, warranting further investigation in broader populations.